Amundi Has $6.90 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Amundi lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 45.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,042 shares of the medical research company’s stock after selling 16,596 shares during the period. Amundi’s holdings in Bio-Rad Laboratories were worth $6,902,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BIO. Strategic Financial Concepts LLC acquired a new stake in Bio-Rad Laboratories during the fourth quarter valued at $3,561,000. Lecap Asset Management Ltd. acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $510,000. Principal Financial Group Inc. lifted its holdings in shares of Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after buying an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. grew its stake in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after buying an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC increased its holdings in Bio-Rad Laboratories by 193.3% in the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after buying an additional 2,287 shares during the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $255.34 on Friday. The firm has a market capitalization of $7.15 billion, a PE ratio of -3.93 and a beta of 0.99. Bio-Rad Laboratories, Inc. has a 1 year low of $244.00 and a 1 year high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $311.97 and its 200 day simple moving average is $328.01.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

BIO has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.